The Lysosomal Storage Disease Treatment Market is expanding due to increased diagnosis rates and innovations in enzyme ...
According to DataM Intelligence, Metabolic Disorders Therapeutics Market Size was valued at US$74.97 billion in 2024 and is ...
Chiesi Group today announced it has entered into an exclusive license agreement with Aliada Therapeutics, a wholly owned ...
A worldwide, exclusive license is being granted to develop and commercialize enzyme replacement therapies using proprietary platform technology.
Chiesi Group signs agreement with Aliada Therapeutics to advance blood-brain barrier-crossing platform technology in lysosomal storage disorders: Parma, Italy Saturday, November 1 ...
GlobalData on MSN
Chiesi and Aliada sign licence deal for enzyme replacement therapies
Chiesi has entered an exclusive licence agreement with Aliada to develop ERTs using BBB-crossing technology for LSDs.
Family-controlled Italian biopharma Chiesi Group has entered into an exclusive license agreement with Aliada Therapeutics, a ...
Delhi HC revives rare-disease crowdfunding portal amid low participation, aiming to enhance funding for critical patient treatments.
The Times of India on MSN
Children Wither Away As Govt’s Funds For Rare Diseases Dry Up
Ten-year-old Abdul Rehman, once full of life, wastes away at AIIMS, appearing frailer with every passing week. He suffers ...
13don MSN
Patient groups urge PM Modi to enforce Delhi HC order to establish National Fund for Rare Diseases
A leading patient group and families of children with ultra-rare diseases across India have appealed to Prime Minister Narendra Modi to direct the Un ...
In its 50th year, JCR Pharmaceuticals, long regarded as one of Japan’s best-kept biotech secrets, is stepping onto the global stage. | Long regarded as one of Japan’s best-kept biotech secrets, JCR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback